Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

  • Gargini, Ricardo
  • Segura-Collar, Berta
  • Herranz, Beatriz
  • García-Escudero, Vega
  • Romero-Bravo, Andrés
  • Núñez, Felipe J.
  • García-Pérez, Daniel
  • Gutiérrez-Guamán, Jacqueline
  • Ayuso-Sacido, Angel
  • Seoane, Joan
  • Pérez-Núñez, Angel
  • Sepúlveda-Sánchez, Juan Manuel
  • Hernández-Laín, Aurelio
  • Castro, María G.
  • García-Escudero, Ramón
  • Ávila, Jesús
  • Sánchez-Gómez, Pilar
Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas. However, how these mutant (mut) proteins affect the tumor microenvironment is still a pending question. Here, we describe that the transcription of microtubule-associated protein TAU (MAPT), a gene that has been classically associated with neurodegenerative diseases, is epigenetically controlled by the balance between wt and mut IDH1/2 in mouse and human gliomas. In IDH1/2 mut tumors, we found high expression of TAU that decreased with tumor progression. Furthermore, MAPT was almost absent from tumors with epidermal growth factor receptor (EGFR) mutations, whereas its trancription negatively correlated with overall survival in gliomas carrying wt or amplified (amp) EGFR. We demonstrated that the overexpression of TAU, through the stabilization of microtubules, impaired the mesenchymal/pericyte-like transformation of glioma cells by blocking EGFR, nuclear factor kappa-light-chain-enhancer of activated B (NF-κB) and the transcriptional coactivator with PDZ-binding motif (TAZ). Our data also showed that mut EGFR induced a constitutive activation of this pathway, which was no longer sensitive to TAU. By inhibiting the transdifferentiation capacity of EGFRamp/wt tumor cells, TAU protein inhibited angiogenesis and favored vascular normalization, decreasing glioma aggressiveness and increasing their sensitivity to chemotherapy., This work was supported by NIH/ NINDS grants R01-NS105556 and R37-ND094804 to M.G.C.; by Ministerio de Economía y Competitividad (Acción Estratégica en Salud) grants PI13/01258 to A.H.-L., PI17/01489 and CP11/00147 to A.A.-S., PI18/00263 to R.G.-E., and PI16/01 278 to J.S.; by “Asociación Española contra el Cancer” grants Investigador Junior to R.G. and GCTRA16015SEDA to J.M.S.-S. and J.S.; and by Ministerio de Economía y Competitividad SAF-2014-53040-P to J.A., RTC-2015-3771-1 to J.S., and SAF2015-65175-R/FEDER to P.S.-G, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Bonfill-Teixidor, Ester|||0000-0002-9260-448X
  • Planas-Rigol, Ester|||0000-0001-5948-2241
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Iurlaro, Raffaella|||0000-0003-1019-6679
  • Arias, Alexandra
  • Cuartas, Isabel
  • Sala-Hojman, Ada
  • Escudero, Laura|||0000-0001-7385-673X
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Huber-Ruano, Isabel
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Marques, Carlota|||0000-0002-8308-5630
  • Braña, Irene|||0000-0002-1068-9601
  • Garralda, Elena|||0000-0002-4412-7842
  • Vieito, María|||0000-0001-7531-343X
  • Squatrito, Juan|||0000-0002-4593-3790
  • Pineda, Estela|||0000-0003-2128-747X
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Espejo, Carmen|||0000-0001-9949-5901
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Tabernero, Josep|||0000-0002-2495-8139
  • Seoane Suárez, Joan|||0000-0002-6541-5974
Cancer response to immunotherapy depends on the infiltration of CD8 T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8 T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8 T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.